Doxa AB (publ) (DOXA.ST)
SEK 0.57
(4.63%)
SEK 0.57
(4.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -259.5 Million SEK | 4.41% |
| 2022 | 40.8 Million SEK | -2.39% |
| 2021 | 41.8 Million SEK | 94.26% |
| 2020 | 21.51 Million SEK | -3.84% |
| 2019 | 22.37 Million SEK | 2.62% |
| 2018 | 21.8 Million SEK | -7.17% |
| 2017 | 23.48 Million SEK | -10.23% |
| 2016 | 26.16 Million SEK | -0.86% |
| 2015 | 26.39 Million SEK | 7.68% |
| 2014 | 24.51 Million SEK | 8.17% |
| 2013 | 22.66 Million SEK | -44.76% |
| 2012 | 41.02 Million SEK | 5.24% |
| 2011 | 38.97 Million SEK | 34.26% |
| 2010 | 29.03 Million SEK | -8.47% |
| 2009 | 31.72 Million SEK | -29.51% |
| 2008 | 45 Million SEK | 11.69% |
| 2007 | 40.29 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 10.5 Million SEK | 7.0% |
| 2024 Q1 | 10 Million SEK | 363.16% |
| 2023 Q1 | 10.5 Million SEK | -26.57% |
| 2023 FY | 42.6 Million SEK | 4.41% |
| 2023 Q2 | 28.3 Million SEK | 169.52% |
| 2023 Q4 | -3.8 Million SEK | -150.0% |
| 2023 Q3 | 7.6 Million SEK | -73.14% |
| 2022 Q1 | 14.5 Million SEK | -29.61% |
| 2022 FY | 40.8 Million SEK | -2.39% |
| 2022 Q4 | 14.3 Million SEK | 138.33% |
| 2022 Q3 | 6 Million SEK | 0.0% |
| 2022 Q2 | 6 Million SEK | -58.62% |
| 2021 FY | 41.8 Million SEK | 94.26% |
| 2021 Q2 | 6.9 Million SEK | 15.0% |
| 2021 Q3 | 8.3 Million SEK | 20.29% |
| 2021 Q4 | 20.6 Million SEK | 148.19% |
| 2021 Q1 | 6 Million SEK | 19.57% |
| 2020 Q1 | 6.2 Million SEK | -2.78% |
| 2020 Q3 | 5.3 Million SEK | 3.92% |
| 2020 Q2 | 5.1 Million SEK | -17.74% |
| 2020 Q4 | 5.01 Million SEK | -5.32% |
| 2020 FY | 21.51 Million SEK | -3.84% |
| 2019 Q4 | 6.37 Million SEK | 25.04% |
| 2019 FY | 22.37 Million SEK | 2.62% |
| 2019 Q3 | 5.1 Million SEK | -7.27% |
| 2019 Q2 | 5.5 Million SEK | 1.85% |
| 2019 Q1 | 5.4 Million SEK | -10.09% |
| 2018 FY | 21.8 Million SEK | -7.17% |
| 2018 Q4 | 6 Million SEK | 25.13% |
| 2018 Q3 | 4.8 Million SEK | -12.73% |
| 2018 Q1 | 5.5 Million SEK | 12.5% |
| 2018 Q2 | 5.5 Million SEK | 0.0% |
| 2017 FY | 23.48 Million SEK | -10.23% |
| 2017 Q3 | 4.9 Million SEK | -26.87% |
| 2017 Q2 | 6.7 Million SEK | 0.0% |
| 2017 Q1 | 6.7 Million SEK | -0.96% |
| 2017 Q4 | 4.88 Million SEK | -0.22% |
| 2016 Q3 | 6 Million SEK | -15.49% |
| 2016 Q2 | 7.1 Million SEK | 14.52% |
| 2016 Q4 | 6.76 Million SEK | 12.75% |
| 2016 FY | 26.16 Million SEK | -0.86% |
| 2016 Q1 | 6.2 Million SEK | -7.37% |
| 2015 FY | 26.39 Million SEK | 7.68% |
| 2015 Q4 | 6.69 Million SEK | 1.41% |
| 2015 Q3 | 6.6 Million SEK | -2.94% |
| 2015 Q2 | 6.8 Million SEK | 7.94% |
| 2015 Q1 | 6.3 Million SEK | 46.14% |
| 2014 Q3 | 5.3 Million SEK | -30.26% |
| 2014 Q1 | 7.3 Million SEK | 20.68% |
| 2014 Q2 | 7.6 Million SEK | 4.11% |
| 2014 Q4 | 4.31 Million SEK | -18.66% |
| 2014 FY | 24.51 Million SEK | 8.17% |
| 2013 Q4 | 6.04 Million SEK | 23.45% |
| 2013 Q1 | 5.7 Million SEK | 42.0% |
| 2013 FY | 22.66 Million SEK | -44.76% |
| 2013 Q3 | 4.9 Million SEK | -19.67% |
| 2013 Q2 | 6.1 Million SEK | 7.02% |
| 2012 Q4 | 4.01 Million SEK | 0.0% |
| 2012 FY | 41.02 Million SEK | 5.24% |
| 2011 FY | 38.97 Million SEK | 34.26% |
| 2010 FY | 29.03 Million SEK | -8.47% |
| 2009 FY | 31.72 Million SEK | -29.51% |
| 2008 FY | 45 Million SEK | 11.69% |
| 2007 FY | 40.29 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AddLife AB (publ) | 3.01 Billion SEK | 108.61% |
| Biotage AB (publ) | 637 Million SEK | 140.738% |
| Bonesupport Holding AB (publ) | 510.93 Million SEK | 150.79% |
| Elekta AB (publ) | 3.39 Billion SEK | 107.655% |
| iZafe Group AB (publ) | 35.92 Million SEK | 822.278% |
| Ortivus AB (publ) | 48.45 Million SEK | 635.571% |
| Ortivus AB (publ) | 48.45 Million SEK | 635.571% |
| Q-linea AB (publ) | -43 Thousand SEK | -603388.372% |
| S2Medical AB (publ) | 20.3 Million SEK | 1378.271% |
| Synsam AB (publ) | 3.76 Billion SEK | 106.898% |